1. Home
  2. PETS vs ANIX Comparison

PETS vs ANIX Comparison

Compare PETS & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

HOLD

Current Price

$2.25

Market Cap

61.6M

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.82

Market Cap

100.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETS
ANIX
Founded
1996
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6M
100.6M
IPO Year
2003
2013

Fundamental Metrics

Financial Performance
Metric
PETS
ANIX
Price
$2.25
$2.82
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
60.1K
111.0K
Earning Date
06-09-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
18.92
12.82
EPS
N/A
N/A
Revenue
$273,800,000.00
$210,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.98
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$2.44
52 Week High
$4.32
$5.46

Technical Indicators

Market Signals
Indicator
PETS
ANIX
Relative Strength Index (RSI) 41.98 43.41
Support Level $2.19 $2.81
Resistance Level $2.44 $3.12
Average True Range (ATR) 0.09 0.16
MACD 0.00 -0.03
Stochastic Oscillator 16.63 15.28

Price Performance

Historical Comparison
PETS
ANIX

About PETS PetMed Express Inc.

PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: